Clinical implications of the oncometabolite succinate in SDHx-mutation carriers

Karin Eijkelenkamp, Thamara E Osinga, Thera P Links, Anouk N A van der Horst-Schrivers*

*Bijbehorende auteur voor dit werk

Onderzoeksoutput: Review articlepeer review

14 Citaten (Scopus)
72 Downloads (Pure)

Samenvatting

Succinate dehydrogenase (SDH) mutations lead to the accumulation of succinate, which acts as an oncometabolite. Germline SDHx mutations predispose to paraganglioma (PGL) and pheochromocytoma (PCC), as well as to renal cell carcinoma and gastro-intestinal stromal tumors. The SDHx genes were the first tumor suppressor genes discovered which encode for a mitochondrial enzyme, thereby supporting Otto Warburg's hypothesis in 1926 that a direct link existed between mitochondrial dysfunction and cancer. Accumulation of succinate is the hallmark of tumorigenesis in PGL and PCC. Succinate accumulation inhibits several α-ketoglutarate dioxygenases, thereby inducing the pseudohypoxia pathway and causing epigenetic changes. Moreover, SDH loss as a consequence of SDHx mutations can lead to reprogramming of cell metabolism. Metabolomics can be used as a diagnostic tool, as succinate and other metabolites can be measured in tumor tissue, plasma and urine with different techniques. Furthermore, these pathophysiological characteristics provide insight into therapeutic targets for metastatic disease. This review provides an overview of the pathophysiology and clinical implications of oncometabolite succinate in SDHx mutations.

Originele taal-2English
Pagina's (van-tot)39-53
Aantal pagina's15
TijdschriftClinical Genetics
Volume97
Nummer van het tijdschrift1
Vroegere onlinedatum12-apr-2019
DOI's
StatusPublished - 2020

Citeer dit